Literature DB >> 11055589

Suppression of type I collagen gene expression by prostaglandins in fibroblasts is mediated at the transcriptional level.

F B Riquet1, W F Lai, J R Birkhead, L F Suen, G Karsenty, M B Goldring.   

Abstract

BACKGROUND: Tissues undergoing a chronic inflammatory process, such as the synovium in rheumatoid arthritis, are characterized by the infiltration of lymphocytes of different subsets and activation of monocyte/macrophages. Interleukin-1 (IL-1), a monocyte/ macrophage product that stimulates synovial fibroblasts to produce matrix metalloproteinases (MMPs), prostaglandins, and other cytokines, also has profound effects on the synthesis of extracellular matrix components such as type I collagen. In previous studies, we have shown that synovial fibroblasts and chondrocytes isolated from human joint tissues are particularly sensitive to prostaglandins, which modulate the effects of IL-1 on collagen gene expression in an autocrine manner.
MATERIALS AND METHODS: BALBc/3T3 fibroblasts were treated with IL-1 and prostaglandins in the absence and presence of indomethacin to inhibit endogenous prostaglandin biosynthesis. Collagen synthesis was analyzed by SDS-PAGE as [3H]proline-labeled, secreted proteins, and prostaglandin production and cyclic adenosine 3',5'-cyclic monophosphate (camp) content were assayed. The expression of type I collagen gene (Col1a1) promoter-reporter gene constructs was examined in transient transfection experiments, and the binding of nuclear factors to the Col1a1 promoter region spanning -222 bp/+ 116 bp was analyzed by DNase I footprinting and electrophoretic mobility shift (EMSA) assays.
RESULTS: IL-1 increased the synthesis of type I and type III collagens in BALBc/3T3 fibroblasts; greater increases were observed when IL-1-stimulated synthesis of PGE2 was blocked by indomethacin. Transient transfection experiments demonstrated dose-dependent inhibition of the-222 bp Col1a1 promoter by exogenously added prostaglandins with the order of potency of PGF2alpha > PGE2 > PGE1 DNase I footprinting showed increased protection, which extended from the region immediately upstream of the TATA box, owing to the binding of nuclear factors from PGE2- or PGE1-treated BALBc/3T3 cells. EMSA analysis showed zinc-dependent differences in the binding of nuclear factors from untreated and prostaglandin-treated cells to the -84 bp/-29 bp region of the Col1a1 promoter.
CONCLUSIONS: These results show that the inhibition of Col1a1 expression by IL-1 in fibroblasts is mediated by prostaglandins at the transcriptional level and suggest that PGE-responsive factors may interact directly or indirectly with basal regulatory elements in the proximal promoter region of the Col1a1 gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055589      PMCID: PMC1949972     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  14 in total

1.  Innovative therapies in the treatment of keloids and hypertrophic scars.

Authors:  Martha H Viera; Sadegh Amini; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-05

2.  Prostaglandin E2 and prostaglandin F2α differentially modulate matrix metabolism of human nucleus pulposus cells.

Authors:  Nam V Vo; Gwendolyn A Sowa; James D Kang; Christopher Seidel; Rebecca K Studer
Journal:  J Orthop Res       Date:  2010-10       Impact factor: 3.494

3.  The TATA-containing core promoter of the type II collagen gene (COL2A1) is the target of interferon-gamma-mediated inhibition in human chondrocytes: requirement for Stat1 alpha, Jak1 and Jak2.

Authors:  Makoto Osaki; Lujian Tan; Bob K Choy; Yasuhiro Yoshida; Kathryn S E Cheah; Philip E Auron; Mary B Goldring
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

Review 4.  Pathogenesis of tendinopathies: inflammation or degeneration?

Authors:  Michele Abate; Karin Gravare Silbernagel; Carl Siljeholm; Angelo Di Iorio; Daniele De Amicis; Vincenzo Salini; Suzanne Werner; Roberto Paganelli
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

5.  Host cell cytokines induced by Chlamydia pneumoniae decrease the expression of interstitial collagens and fibronectin in fibroblasts.

Authors:  Jürgen Baumert; Karl-Hermann Schmidt; Annett Eitner; Eberhard Straube; Jürgen Rödel
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

6.  Leukotriene B4 at low dosage negates the catabolic effect of prostaglandin E2 in human patellar tendon fibroblasts.

Authors:  Bhavani P Thampatty; Hee-Jeong Im; James H-C Wang
Journal:  Gene       Date:  2006-02-20       Impact factor: 3.688

7.  An essential role for fibronectin extra type III domain A in pulmonary fibrosis.

Authors:  Andrés F Muro; Federico A Moretti; Bethany B Moore; Mei Yan; Rachelle G Atrasz; Carol A Wilke; Kevin R Flaherty; Fernando J Martinez; Jessica L Tsui; Dean Sheppard; Francisco E Baralle; Galen B Toews; Eric S White
Journal:  Am J Respir Crit Care Med       Date:  2007-12-20       Impact factor: 21.405

8.  Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability.

Authors:  Hiroto Mitsui; Tomoki Aoyama; Moritoshi Furu; Kinya Ito; Yonghui Jin; Takayuki Maruyama; Toshiya Kanaji; Shinsei Fujimura; Hikaru Sugihara; Akio Nishiura; Takanobu Otsuka; Takashi Nakamura; Junya Toguchida
Journal:  Arthritis Res Ther       Date:  2011-09-14       Impact factor: 5.156

9.  Inducible nitric oxide synthase links NF-kappaB to PGE2 in polyunsaturated fatty acid altered fibroblast in-vitro wound healing.

Authors:  Yi Jia; John J Turek
Journal:  Lipids Health Dis       Date:  2005-07-12       Impact factor: 3.876

10.  TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells.

Authors:  Catherine Baugé; Sylvain Leclercq; Thierry Conrozier; Karim Boumediene
Journal:  BMC Complement Altern Med       Date:  2015-07-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.